^
BIOMARKER:

CRBN overexpression

i
Other names: CRBN, Cereblon, Protein Cereblon, Mental Retardation, Non-Syndromic, Autosomal Recessive, 2A, Protein X 0001, MRT2A, MRT2
Entrez ID:
Related biomarkers:
5ms
Multiple Myeloma Patient Tumors With High Levels of Cereblon Exon-10 Deletion Splice Variant Upregulate Clinically Targetable Pro-Inflammatory Cytokine Pathways. (PubMed, Front Genet)
Immunomodulatory drugs (IMiDs), including lenalidomide and pomalidomide, are used in the routine treatment for multiple myeloma (MM) patients...Interestingly, we found that an EZH2 sensitivity gene expression signature also correlated with high BATF or venetoclax sensitivity scores in these tumors. Together, these data provide a rationale for investigating EZH2 inhibitors or venetoclax in combination with the next generation CRBN-targeting agents, such as CELMoDs, for patients overexpressing the CRBN exon-10 splice variant.
Journal
|
IFNG (Interferon, gamma) • CRBN (Cereblon) • IKZF1 (IKAROS Family Zinc Finger 1) • TNFA (Tumor Necrosis Factor-Alpha) • IL10 (Interleukin 10)
|
CRBN expression • CRBN overexpression
|
Venclexta (venetoclax) • lenalidomide • Tazverik (tazemetostat) • pomalidomide
6ms
Gene Mutation and Overexpression of Newly Diagnosed Multiple Myeloma Patients (PubMed, Zhongguo Shi Yan Xue Ye Xue Za Zhi)
There are multiple gene mutations and overexpression in NDMM. However, there is no dominated single mutation or overexpression of genes. The most common gene mutations are those in the RAS/MAPK pathway and the genes of cyclin family CCND are overexpression.
Journal • IO biomarker
|
KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • NRAS (Neuroblastoma RAS viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2) • FGFR3 (Fibroblast growth factor receptor 3) • CCND1 (Cyclin D1) • CRBN (Cereblon) • CCND3 (Cyclin D3) • CCND2 (Cyclin D2) • PRDM1 (PR/SET Domain 1) • TENT5C (Terminal Nucleotidyltransferase 5C)
|
MYC overexpression • CCND1 overexpression • FGFR3 overexpression • CRBN expression • CRBN overexpression • KRAS overexpression • Chr del(13)(q14) • FGF3 overexpression
9ms
ARV-825 Demonstrates Antitumor Activity in Gastric Cancer via MYC-Targets and G2M-Checkpoint Signaling Pathways. (PubMed, Front Oncol)
ARV-825 displayed higher anticancer efficiency in gastric cancer cells than OTX015 and JQ1. ARV-825, a BRD4 inhibitor, could effectively suppress the growth and elevate the apoptosis of gastric cancer cells via transcription downregulation of c-MYC and PLK1. These results implied that ARV-825 could be a good therapeutic strategy to treat gastric cancer.
Journal • PARP Biomarker
|
MYC (V-myc avian myelocytomatosis viral oncogene homolog) • CRBN (Cereblon) • CASP3 (Caspase 3) • PLK1 (Polo Like Kinase 1) • BRD4 (Bromodomain Containing 4)
|
MYC expression • CRBN expression • CRBN overexpression
|
JQ-1 • birabresib (OTX015) • ARV-825